EPIDATUM

Name: EPIDATUM - AI Visibility Score
Creator: Engagemii
Published: 2026-07-16T01:38:22.901Z
License: https://creativecommons.org/licenses/by/4.0/

Unclaimed

AEO Score: 4/10

Monitoring for AI engine activity

In the Engagemii AEO index

#315,857 of 477,826 in Healthcare for AI visibility

epidatum.com

What this score means

Your AEO score measures whether AI search engines (ChatGPT, Claude, Perplexity, Gemini) can actually read your site and cite it in answers. Two-thirds of websites are invisible to them. EPIDATUM just got measured.

4/10 means EPIDATUM is borderline visible. AI bots can crawl your site but your structured-data signals are thin. You are at risk of being skipped when buyers ask AI for a recommendation.

About EPIDATUM

A regional director who was employed at the research organisation Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial.

Key Topics

Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial

SARS-CoV-2 variants of concern and variants under investigation in England

UK government secures groundbreaking COVID-19 antivirals

Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001

Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults

Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study